Search
for
Sort by
Research 211–240 of 778
- Oclacitinib Treatment and Surgical Management in a Case of Periocular Eosinophilic Furunculosis and Vasculitis with Secondary Eyelid Fusion in a Diabetic Cat
- Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
- Deciphering the Complex Immunopathogenesis of Alopecia Areata
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Janus kinase inhibitors for alopecia areata: A narrative review
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Modern dermatology brings treatment even for alopecia areata
- Efficacy of tofacitinib in pediatric alopecia universalis
- Janus kinase inhibition for the treatment of refractory frontal fibrosing alopecia: A case series and review of the literature
- Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review
- Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series
- 44096 Efficacy in Subgroups related to Disease Characteristics in Patients with Alopecia Areata from BRAVE-AA1 and BRAVE-AA2
- 056 IL-15 prolongs hair growth and operates as a guardian of human hair follicle immune privilege
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
- Abrocitinib Improved Dupilumab-Resistant Severe Atopic Dermatitis with Comorbid Mild Alopecia Areata in a 12-Year-Old Boy: A Case Report with 1-Year Follow-Up
- Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
- Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- 219 STAT5 activation in the dermal papilla is important for hair follicle growth phase induction, hair follicle regeneration and wound healing
- 217 The adenosine-generating ecto-enzyme CD73 regulates human hair growth
- Real-World Evidence for Baricitinib in the Treatment of Atopic Dermatitis and Alopecia Areata: Systematic Literature Review 2020–2023
- Patient-Reported Hair Loss and Its Impacts as Measured by the Alopecia Areata Patient Priority Outcomes Instrument in Patients Treated with Ritlecitinib: The ALLEGRO Phase 2b/3 Randomized Clinical Trial
- Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- A Bibliometric Analysis of Alopecia Areata Literature over the Past 50 Years.
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris